Elutia Inc. (ELUT)
$
1.8
+0.15 (8.33%)
Key metrics
Financial statements
Free cash flow per share
-0.7576
Market cap
74 Million
Price to sales ratio
3.1213
Debt to equity
-0.8073
Current ratio
0.8146
Income quality
0.7245
Average inventory
4.1 Million
ROE
0.8519
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elutia Inc. is a commercial-stage company that specializes in the development and commercialization of drug-eluting biologics products tailored for neurostimulation, wound care, and breast reconstruction within the United States. Operating through three segments—Device Protection, Women's Health, and Cardiovascular—the company markets a range of innovative solutions. One of its notable products is the CanGaroo Envelope, designed to house cardiac implantable electronic devices, including pacemakers and internal defibrillators. Elutia Inc. is also advancing the CanGarooRM, which merges the CanGaroo envelope with antibiotics to mitigate the risk of infection following the surgical implantation of electronic devices. In addition, the company offers ProxiCor for cardiac tissue repair and pericardial closure, and Tyke, an extracellular material utilized in repairing cardiac structures in neonate and infant patients. The VasCure patch material is another product aimed at repairing or reconstructing peripheral vasculature. Furthermore, the company provides SimpliDerm, utilizing human acellular dermal matrices for various tissue repair and reconstruction applications, including sports medicine, hernia repairs, trauma reconstruction, and breast reconstruction surgeries after mastectomy. Elutia Inc. sells its products through a dedicated sales force, independent agents, and various distributors. The diluted EPS is -$1.86 accounting for potential share dilution. The net total of other income and expenses is -$18,471,000.00 reflecting non-core financial activities. The income before tax ratio is -2.22 reflecting the pre-tax margin, and the net income ratio stands at -2.21 demonstrating the company's profitability margin. Additionally, the weighted average number of diluted shares outstanding is 29,071,113.00 indicating potential dilution effects. With a market capitalization of $74,008,195.00 Elutia Inc. is classified as a small-cap player within the health technology space. The stock is affordable at $1.65 thus appealing to budget-conscious investors. Nevertheless, it is noteworthy that the stock has a low average trading volume of 42,077.00 suggesting lower market activity. As a key entity in the Biotechnology industry, Elutia Inc. contributes significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, which is recognized for driving innovation and growth across various fields. This strategic positioning within the market sets Elutia Inc. apart as a potential contender in its segment.
Is Elutia Inc. (ELUT) a good investment?
Investing in Elutia Inc. (ELUT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Elutia Inc. (ELUT)'s stock forecast?
Analysts predict Elutia Inc. stock to fluctuate between $1.61 (low) and $5.24 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elutia Inc.'s market capitalization?
As of 2025-05-30, Elutia Inc.'s market cap is $74,008,195, based on 41,115,664 outstanding shares.
How does Elutia Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elutia Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elutia Inc. (ELUT) stock?
To buy Elutia Inc. (ELUT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELUT. Place an order (Market, Limit, etc.).
What is the best time to invest in Elutia Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Elutia Inc. perform in the last earnings report?
Revenue: $24,375,000 | EPS: -$1.86 | Growth: -10.14%.
Where can I find Elutia Inc.'s investor relations reports?
Visit https://elutia.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elutia Inc.?
You can explore historical data from here
What is the all-time high and low for Elutia Inc. stock?
All-time high: $5.24 (2024-07-01) | All-time low: $1.10 (2023-09-11).
What are the key trends affecting Elutia Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
3 days ago
— Innovative approach accelerates new product development and testing — — Innovative approach accelerates new product development and testing —
seekingalpha.com
20 days ago
Elutia Inc. (NASDAQ:ELUT ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Matt Steinberg - FINN Partners Randal Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Matt Park - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2025 Financial Results Conference Call.
globenewswire.com
23 days ago
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m.
globenewswire.com
a month ago
Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment.
globenewswire.com
a month ago
SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
globenewswire.com
a month ago
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief Scientific Officer, will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.
globenewswire.com
a month ago
— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice.
globenewswire.com
2 months ago
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance.
globenewswire.com
2 months ago
SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:
globenewswire.com
2 months ago
Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society's annual meeting (HRS 2025).
See all news
